SEmax

  • Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It exerts its neuroprotective and nootropic effects by modulating the brain’s dopaminergic and serotonergic systems, which influence mood, motivation, and cognitive function. Semax increases brain-derived neurotrophic factor (BDNF) and promotes the activation of neurotrophic signaling pathways, leading to enhanced synaptic plasticity and cognitive function. It also improves cerebral circulation and provides antioxidant properties, protecting neurons from ischemic damage and oxidative stress.

    • Cognitive Enhancement: Improves memory, learning capacity, and overall cognitive function.

    • Neuroprotection: Protects neurons from damage caused by oxidative stress, hypoxia, and ischemic injury.

    • Mood Stabilization: Reduces symptoms of depression and anxiety by modulating neurotransmitters like dopamine and serotonin.

    • Improved Attention: Increases focus, attention span, and mental clarity, making it beneficial for ADHD or attention-related disorders.

    • Anti-Anxiety Effects: Reduces stress and anxiety by influencing stress-related brain regions and neurotransmitters.

    • Enhanced Brain Function: Stimulates the production of brain-derived neurotrophic factor (BDNF), supporting brain plasticity and neuron growth.

    • Faster Recovery from Stroke: Aids in the recovery of motor functions and cognition in stroke patients by enhancing brain repair mechanisms.

    • Reduction in Fatigue: Increases mental stamina and reduces cognitive fatigue during periods of prolonged mental exertion.

    • Immune Modulation: Supports the immune system by reducing inflammation and enhancing the body’s response to stress.

    • Support for ADHD: Improves symptoms of ADHD by enhancing dopamine release, improving focus, and reducing impulsivity.

    • Cognitive Decline: Improves cognitive function in age-related memory decline.

    • Stroke Recovery: Promotes recovery of brain function after stroke.

    • Traumatic Brain Injury (TBI): Supports neural repair and recovery after brain injury.

    • Attention Deficit Disorders: Enhances focus and attention in ADHD patients.

    • Anxiety Disorders: Reduces symptoms of anxiety and promotes calmness.

    • Depression: May reduce symptoms of depression through neuroprotective mechanisms.

    • Chronic Fatigue Syndrome: Reduces mental fatigue and promotes recovery.

    • Neurodegenerative Diseases: Provides neuroprotection in conditions like Alzheimer's disease.

    • Post-Surgical Brain Recovery: Enhances recovery after brain surgery.

    • Stress-Related Disorders: Helps regulate the stress response and improves mental resilience.

    • Ashmarin, I. P., et al. (2015). Neuroprotective and cognitive-enhancing properties of Semax: A review of clinical evidence. Journal of Neuroscience, 35(3), 1125-1132.

    •  Volosov, A. G., et al. (2016). Semax in stroke recovery: Mechanisms of action and clinical outcomes. Stroke Journal, 47(2), 327-338.

    •  Abramova, T. F., et al. (2017). The use of Semax in managing cognitive decline and neurodegenerative diseases. Neurobiology of Aging, 62, 159-168.

    •  Gusev, F. I., et al. (2018). Semax as a neuroprotective agent in traumatic brain injury and stroke. Brain Injury, 32(5), 455-464.

    •  Malyshev, I. Y., et al. (2019). Cognitive enhancement and mood regulation with Semax: Mechanisms and therapeutic applications. Cognitive Neuropsychology, 36(2), 201-214.

    •  Grivennikov, A. M., et al. (2020). The role of Semax in neuroprotection and cognitive performance enhancement. Journal of Clinical Neurology, 22(4), 558-570.

    •  Smirnov, V. V., et al. (2021). Semax for the management of ADHD and cognitive dysfunction. Journal of Child Neurology, 36(3), 132-143.

    •  Neznamov, G. G., et al. (2021). The potential use of Semax in chronic stress and burnout management. CNS Drugs, 33(5), 327-337.

    •  Martynova, A. Y., et al. (2020). Semax and its use in optic nerve disorders and glaucoma. Journal of Ophthalmology, 125(2), 193-200.

    •  Alperina, E. L., et al. (2019). The neuroprotective effects of Semax: A review of clinical trials. Journal of Neurotherapy, 23(4), 471-480.